Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
South Korea · Delayed Price · Currency is KRW 6,100.00
-70.00 (-1.13%)
At close: Apr 9, 2026
Seoulin Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 77,091 | 75,410 | 89,569 | 104,708 | 80,539 |
Other Revenue | -0 | -0 | - | - | - |
| 77,091 | 75,410 | 89,569 | 104,708 | 80,539 | |
Revenue Growth (YoY) | 2.23% | -15.81% | -14.46% | 30.01% | 23.74% |
Cost of Revenue | 59,810 | 56,450 | 69,699 | 80,417 | 59,469 |
Gross Profit | 17,282 | 18,961 | 19,871 | 24,292 | 21,070 |
Selling, General & Admin | 14,010 | 14,697 | 15,016 | 12,475 | 11,144 |
Research & Development | 935.02 | 1,214 | 785.23 | 870.46 | 786.82 |
Amortization of Goodwill & Intangibles | 81.45 | 92.26 | 112.83 | 163.33 | 459.01 |
Other Operating Expenses | 467.42 | 483.24 | 441.22 | 396.47 | 382.27 |
Operating Expenses | 16,590 | 18,008 | 17,376 | 15,094 | 13,619 |
Operating Income | 691.62 | 952.67 | 2,495 | 9,198 | 7,451 |
Interest Expense | -644.56 | -329.7 | -2,482 | -2,287 | -224.55 |
Interest & Investment Income | 743.58 | 996.22 | 2,051 | 1,637 | 303.78 |
Earnings From Equity Investments | 7.54 | 88.53 | 85.1 | 121.01 | 114.5 |
Currency Exchange Gain (Loss) | -138.9 | 10.01 | -308.95 | -63.7 | -178.86 |
Other Non Operating Income (Expenses) | 1,025 | 666.37 | 3,441 | 3,808 | -397.15 |
EBT Excluding Unusual Items | 1,684 | 2,384 | 5,280 | 12,413 | 7,069 |
Gain (Loss) on Sale of Investments | -421.13 | 1,986 | -4,966 | 2,011 | 160.11 |
Gain (Loss) on Sale of Assets | -0 | -13.69 | -31.42 | -1.06 | 14,153 |
Asset Writedown | -373.89 | -152.6 | - | -393.03 | -1,044 |
Other Unusual Items | - | -648.11 | -2,211 | - | - |
Pretax Income | 888.9 | 3,556 | -1,929 | 14,029 | 20,338 |
Income Tax Expense | 315.15 | 415.34 | 394.29 | 3,464 | 4,459 |
Earnings From Continuing Operations | 573.75 | 3,140 | -2,323 | 10,565 | 15,879 |
Earnings From Discontinued Operations | - | - | - | 29.47 | -111.04 |
Net Income to Company | 573.75 | 3,140 | -2,323 | 10,595 | 15,768 |
Minority Interest in Earnings | 158.23 | -226.34 | 2,206 | -435.72 | -178.88 |
Net Income | 731.98 | 2,914 | -117.55 | 10,159 | 15,589 |
Net Income to Common | 731.98 | 2,914 | -117.55 | 10,159 | 15,589 |
Net Income Growth | -74.88% | - | - | -34.84% | 218.64% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 13 | 9 | 9 | 11 | 9 |
Shares Change (YoY) | 53.00% | -2.96% | -19.46% | 23.72% | -0.07% |
EPS (Basic) | 85.00 | 335.00 | -13.11 | 1131.84 | 1733.06 |
EPS (Diluted) | 55.00 | 335.00 | -13.11 | 780.07 | 1732.89 |
EPS Growth | -83.58% | - | - | -54.98% | 218.90% |
Free Cash Flow | 4,367 | -4,660 | -14.95 | -4,817 | 7,984 |
Free Cash Flow Per Share | 328.13 | -535.72 | -1.67 | -432.86 | 887.61 |
Gross Margin | 22.42% | 25.14% | 22.18% | 23.20% | 26.16% |
Operating Margin | 0.90% | 1.26% | 2.79% | 8.78% | 9.25% |
Profit Margin | 0.95% | 3.86% | -0.13% | 9.70% | 19.36% |
Free Cash Flow Margin | 5.67% | -6.18% | -0.02% | -4.60% | 9.91% |
EBITDA | 1,855 | 2,318 | 3,781 | 10,215 | 9,381 |
EBITDA Margin | 2.41% | 3.07% | 4.22% | 9.75% | 11.65% |
D&A For EBITDA | 1,163 | 1,365 | 1,287 | 1,017 | 1,930 |
EBIT | 691.62 | 952.67 | 2,495 | 9,198 | 7,451 |
EBIT Margin | 0.90% | 1.26% | 2.79% | 8.78% | 9.25% |
Effective Tax Rate | 35.45% | 11.68% | - | 24.69% | 21.92% |
Advertising Expenses | 348.51 | 357.36 | 227.45 | 119.05 | 141.61 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.